基质金属蛋白酶9及其复合物在乳腺癌患者尿中的表达

目的　探讨基质金属蛋白酶 9(MMP 9)及其复合物在乳腺癌患者尿中表达的临床意义。　方法　采用明胶酶电泳法、Western印迹法 ,观察 97例乳腺癌患者、4 1例乳腺良性疾病患者和 6 0例正常人尿中MMP 9及其复合物的表达状况。　结果　乳腺癌患者MMP 9及其复合物表达率分别为76 2 9%、6 4 95 % ;乳腺良性疾病患者为 4 6 34%、4 3 90 % ;正常人为 2 3 33%、2 3 33%。乳腺癌患者MMP 9及其复合物表达水平与乳腺良性疾病患者和正常人比较 ,差异有非常显著性意义 (χ2 =7 4 5 6 ,P <0 0 1)。乳腺癌患者尿中MMP 9及其复合物表达与淋巴结转移有关 (χ2 =5 2 0 6 ,P <0 0 5 ) ,与肿瘤大小、TNM分期、年龄、绝经前后、雌激素受体表达无关。　结论　尿中MMP 9及其复合物表达对判定乳腺癌淋巴结的转移具有重要意义。对乳腺癌早期预防及普查可能具有重要意义。

Expression of matrix metalloproteinase-9 and its complex in the urine of breast cancer patients

OBJECTIVE: To investigate the expression and clinical significance of matrix metalloproteinase-9 and its complex in the urine of the patient with breast cancer. METHODS: Using substract gel electrophoresis and western-blot analysis, expressions of MMP-9 and MMP-9/NGAL complex in breast cancer (n = 97), breast benign (n = 41) and normal (n = 60) were observed. RESULTS: There MMP-9 and MMP-9/NGAL complex expressions were 76.29% and 64.95% in breast cancer, 46.34% and 43.90% in breast benign, and 23.33% in normal respectively. The MMP-9 and MMP-9/NGAL complex expressions were higher in breast cancer than those in breast benign and in normal (chi(2) = 7.456, P < 0.01). MMP-9 and MMP-9/NGAL complex expressions in urine of breast cancer had not any relationship with tumor size, TNM stage, patient age, menopause status as well as ER status, but was correlated to lymphatic node status (chi(2) = 5.206, P < 0.05). CONCLUSIONS: MMP-9 and MMP-9/NGAL complex expressions in urine are significant in estimating lymphatic node metastasis in breast cancer and a valuable early prognostic factors and screening in breast cancer.